Beijing Bohui Innovation Biotechnology Group (300318.SZ): The controlling subsidiary terminated the relevant freeze-dried human rabies vaccine (serum-free Vero cell) project cooperation agreement and drug clinical trials.

Gelonghui Finance · Sep 24 06:06

On September 24, Gelonghui announced that Beijing Bohui Innovation Biotechnology Group (stock code 300318.SZ) disclosed that its holding subsidiary, Bohui Biopharmaceutical Co., Ltd. (formerly known as Ch Env Tech&Bio Pharmaceuticals Co., Ltd., hereinafter referred to as 'Langfang Bohui'), signed a 'Project Cooperation Contract' in January 2020 with Chengdu Baiote Biological Technology Co., Ltd. (hereinafter referred to as 'Baiote Biological'), jointly applying for the clinical trial of freeze-dried human rabies vaccine (serum-free Vero cells) completed by Baiote Biological. In July 2020, the vaccine obtained the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration. In September 2024, Langfang Bohui signed a Supplementary Agreement of the '' with Baiote Biological and other relevant parties, stipulating that upon meeting the conditions, the 'Project Cooperation Contract' signed by both parties in January 2020 will be terminated, and the clinical trial of the freeze-dried human rabies vaccine (serum-free Vero cells) jointly developed by both parties will be terminated. Recently, Langfang Bohui received full compensation from Baiote Biological, and the 'Project Cooperation Contract' was officially terminated.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

博晖创新(300318.SZ)：控股孙公司终止相关冻干人用狂犬病疫苗(无血清Vero细胞)项目合作合同及药物临床试验

Beijing Bohui Innovation Biotechnology Group (300318.SZ): The controlling subsidiary terminated the relevant freeze-dried human rabies vaccine (serum-free Vero cell) project cooperation agreement and drug clinical trials.

Risk Disclaimer

Statement